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Regarding the follow-up, it is tempting to 
speculate that in the future a difference in 
local recurrence will become apparent and 
that the trend in lower overall mortality 
will disappear, but neither our data1 nor 
previous trial results support this 
speculation. Statistically, to use median 
follow-up on its own without taking into 
account the absolute number of patients is 
inappropriate. Biologically, the temporal 
distribution of local recurrence shows that 
the first 2–3 year period covers the peak 
hazard of local recurrence after surgery 
(see figure 2 in Cheng and colleagues' 
paper2). Importantly, results from various 
clinical trials have shown that the effect of 
local therapy such as surgery or radiation 
is mainly seen in the first 5 years, with the 
peak of the hazard by the first 2–3 years. 
The lines representing local recurrence 
between radiotherapy and no radiotherapy 
in Kaplan-Meier plots remain almost 
parallel after 5 years in the NSABP B06, 
NSABP B04, and the Oxford Overview. 
The conclusion of the 25-year follow-up of 
the Swedish trial3 of radiotherapy versus 
no radiotherapy was explicit: 
“Radiotherapy protects against recurrences 
during the first 5 years of follow-up.” 
Whatever difference was going to be noted 
at 25 years was already seen at 5 years, 
with most of the difference already seen by 
2–3 years (as seen figure 2A in Wickberg 
and colleagues' paper3). The TARGIT-A 
trial1has a substantial number of patients 
(n=1222) with a median follow-up of 5 
years, and 2232 patients had a median 
follow-up of nearly 4 years. 
Regarding non-breast cancer deaths, we 
found that in the 52 deaths we have 
recorded so far, the ratio of 
TARGIT:EBRT was 17:35; such a notable 
baseline imbalance in cardiac morbidity 
favouring TARGIT seems unlikely in a 
randomised trial of this size. We noted a 
significant difference in non-breast cancer 
mortality with a high degree of confidence 
(p=0·0086), which seems to lead to a trend 
in reduced overall mortality with 
TARGIT.1 
Our data are consistent with the recent 
analysis of Darby and colleagues.4 They 
reported that the risk is highest in the first 
10 years—during this period, the risk of 
cardiac mortality is increased by 16·3% 
(95% CI 3·0–64·3)—ie, a risk ratio of 
1·163 (1·03–1·643) per Gy.4 Presence of 
ischaemic heart disease (equally balanced 
between cases and controls) has a 
multiplicative effect and the risk ratio rises 
to 13·4% (95% CI 7·65–23·58) per Gy. As 
the risk increases linearly with dose, for a 
typical patient with an exposure of 3 Gy, 
the risk would be three-times higher with a 
relatively wide upper confidence limit. 
These estimates are consistent with the 
TARGIT-A trial results.1 
One might expect irradiation for left-sided 
cancers to result in higher cardiac toxic 
effects. However, the ratio of cardiac risk 
of left:right sided cancers is small (1·34 as 
per Darby and colleagues).4Furthermore, 
Darby and colleagues4 recorded no 
significant effect of laterality on cardiac 
toxic effects per Gy. With modern 
radiotherapy designed to reduce cardiac 
dose, the absolute difference between sides 
is likely to be even lower and undetectable 
with few events. So an absence of a 
difference between the left and right sides 
should not be interpreted as an absence of 
cardiac toxicity. 
In the TARGIT-A trial,1 the 5-year risk of 
non-breast cancer mortality was 1·4% 
(TARGIT) versus 3·5% (EBRT). The 
absolute difference in non-breast-cancer 
mortality was 2·1%, about a third of which 
(0·6%) was from cardiac causes. This 
small increase in non-breast cancer 
mortality might have been uncovered early 
in the TARGIT-A trial because of the 
otherwise excellent outcome from breast 
cancer (5-year mortality 2·2%). In older 
trials, this small but lethal effect might 
have been masked until the early high 
breast cancer mortality (eg, 30% at 5 years 
in the CRC1 trial) diminished in later 
years. 
Furthermore, intraoperative irradiation of a 
fresh tumour bed has been shown to 
abrogate the stimulatory and inflammatory 
effects of surgical wounding.5 Could this 
possibly have systemic beneficial effects 
that contribute to the reduction in non-
breast-cancer mortality? This bold 
conjecture is supported by the observation 
of a significant reduction in non-breast 
cancer mortality when patients receive 
TARGIT plus EBRT compared with 
EBRT alone.6 The hypothesis can be 
fortuitously tested in the TARGIT-B 
superiority trial in higher risk women 
(TARGIT boost plus EBRT vsEBRT boost 
plus EBRT). 
Although non-inferiority trials are 
becoming more common, especially when 
cure rates are high and a reduction in 
treatment toxicity without a loss of 
efficacy is desirable, the concept of non-
inferiority can be difficult to grasp. The 
TARGIT-A trial was such a non-inferiority 
trial, which means that even if there is a 
significant difference, as long as it is less 
than a prespecified value (2·5% in the 
TARGIT-A trial), the two groups are 
judged non-inferior to each other. In these 
circumstances, less expensive, less toxic, 
or more convenient treatment becomes the 
preferred choice. 
Furthermore, we had prespecified that the 
significant p value for difference for the 
log-rank test would be less than 0·01 for 
local recurrence—as this was the second 
such analysis. So the 2% difference was 
not only within the non-inferiority margin 
but also, since the p value was 0·04, 
strictly speaking, it was not statistically 
significant. 
We have used the standard method of 
using binomial proportions to calculate the 
non-inferiority statistic. Single 5-year 
point estimates do not represent absolute 
events and can lead to erroneous 
conclusions, especially when the event rate 
is low. The method we have used makes a 
comprehensive assessment of the whole 
follow-up period, which stretches from the 
day of randomisation to the longest 
follow-up of more than 12 years and 
includes all events in that period. To 
address the issue of follow-up, we repeated 
the analysis by restricting the cohorts 
randomised early in the trial including the 
group of 1222 patients with a median 
follow-up of 5 years. The multiple 
comparisons issue does not apply as we 
have not chosen one of several 
comparisons to make our conclusions. We 
have used all three cohorts together to 
inform the discussion and clearly stated 
that they are nested within each other. 
Exploratory analysis of regional 
recurrence by intention to treat showed no 
difference between the two randomised 
groups. Furthermore, omission of EBRT 
did not increase axillary recurrence when 
analysed as per treatment received: the 
number of axillary recurrences were five 
of 1613 when EBRT was not given versus 
six of 1762 when EBRT was given; 5-year 
risks 0·68% (95% CI 0·28–1·6) versus 
0·82% (0·34–2·02), HR 0·84 (0·26–2·74, 
p=0·8).7 
Despite a clear description of how the 
prepathology and postpathology strata 
were prespecified during the course of the 
trial, Jack Cuzick refers to these as 
subgroups. He suggests that inability to 
find heterogeneity is a proof of its absence. 
The total number of recurrences is low, 
and there might not be enough power to 
detect heterogeneity between the two strata 
even though it might exist. In fact, a Cox 
proportional hazards analysis showed that 
the timing of randomisation variable was 
significant. Furthermore, the formal test 
for non-inferiority showed that although 
prepathology TARGIT was non-inferior, 
postpathology was not. We have been 
cautious in our discussion.1 
In response to Jay Harness and colleagues, 
we believe that calculaton of the dose to 
the heart in only those who died of 
myocardial infarction is not meaningful 
when its proportional attribution to the 
death is small. Additionally, no patient 
who was randomly assigned to EBRT but 
received TARGIT died of a myocardial 
infarction. We did not record detailed 
cardiovascular assessment and excluded 
only those patients with severe 
comorbidities. Finally, we included deaths 
from stroke and ischaemic bowel under 
cardiovascular, not cardiac, events. 
We believe that clinicians and health-care 
policy makers should not deny suitable 
patients the opportunity to complete their 
treatment in one combined procedure that 
not only reduces toxic effects and saves 
20–30 visits to a radiotherapy centre, but 
also in many parts of the world might 
permit breast conservation rather than 
mastectomy. 
We declare that we have no other 
competing interests than those stated in the 
original Article.1 
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